SALT LAKE CITY, May 6, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize energy to treat cancer, today announced that an abstract featuring the use of MicroThermX® technology by radiologist Sohail G. Contractor M.D., a leading expert in the field of interventional oncology, was accepted and will be presented as a poster at World Conference on Interventional Oncology (WCIO) 2015 in New York City.
Dr. Contractor's published scientific research paper on liver tumor ablation is titled "Percutaneous thermal ablation of liver tumor using microwave and radio frequency technique – A Retrospective Review." The purpose of this retrospective chart review study was to gather data on preliminary outcomes from patients who had undergone percutaneous thermal ablation at the University Hospital, Newark, New Jersey in 2011 through 2014.
"This is an important scientific peer review study of our market leading microwave ablation technology," said Clint Carnell, CEO of Perseon. "This retrospective analysis confirms the clinical utility of microwave ablation to effectively eradicate or provide effective local control of liver cancer. Dr. Contractor's research and poster at WCIO 2015 is exactly the type of peer-to-peer education and advocacy that is our primary focus in driving awareness and adoption of our MicroThermX solution across the field of Life Sciences."
WCIO is being held May 6 – 9, 2015 in New York City.
Now in its 11th year, WCIO brings together medical experts from around the world for a multidisciplinary summit, including physicians, nurses, advanced practice providers, physician assistants, and radiology technologists. With an expected audience of more than 600 participants, WCIO 2015 offers more opportunities for interaction and time for exhibitors to meet with attendees. As the largest international event in interventional oncology, WCIO 2015 is a must for those interested in meeting with influencers in the field.
For more information about WCIO 2015 please visit http://wcioevents.org/.
Perseon Corporation invests its resources in fighting humanity's worst disease: cancer. Perseon's people are dedicated to finding innovative technologies and means to deliver energy solutions to healthcare providers and patients around the world. MicroThermX® treats soft tissue tumors with precision-focused energy, expanding the options and broadening the opportunities for cancer treatment.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 email@example.com